低卒中风险房颤患者的口服抗凝治疗:多中心观察性研究
本研究在瑞典、丹麦、挪威和苏格兰纳入59 076例低卒中风险(非性别相关CHA2DS2-VASc评分1分)房颤患者,比较NOAC、VKA与未治疗者的卒中和大出血发生率。观察性数据显示,NOAC治疗可能较未治疗或VKA治疗具有正向净临床获益,该问题需通过随机对照试验验证。
要点
- 低卒中风险房颤患者中,NOAC较未治疗降低卒中风险(HR 0.72),且不增加颅内出血。
- NOAC较VKA颅内出血风险更低(HR 0.63),卒中风险相似。
- VKA较未治疗卒中风险 tended lower,但颅内出血 tended higher。
核心结论
- 观察性数据提示,低卒中风险房颤患者中NOAC治疗可能较未治疗或VKA治疗具有正向净临床获益。
研究设计与样本
- 多国队列研究,纳入瑞典、丹麦、挪威和苏格兰共59 076例低卒中风险房颤患者。
- 采用逆概率治疗加权(IPTW)Cox回归比较NOAC、VKA与未治疗者的卒中和大出血发生率。
主要发现
- 未治疗患者缺血性卒中发生率为0.70/100人年,出血发生率也为0.70/100人年。
- NOAC较未治疗:卒中HR 0.72(95%CI 0.56-0.94),颅内出血HR 0.84(95%CI 0.54-1.30)。
- VKA较未治疗:卒中HR 0.81(95%CI 0.59-1.09),颅内出血HR 1.37(95%CI 0.88-2.14)。
- NOAC较VKA:卒中HR 0.92(95%CI 0.70-1.22),颅内出血HR 0.63(95%CI 0.42-0.94)。
临床怎么用
- 低卒中风险房颤患者抗凝决策需个体化,NOAC可能较VKA或未治疗提供更优净获益。
局限性
- 为观察性研究,存在残余混杂可能,结论需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: There is currently no consensus on whether atrial fibrillation (AF) patients at low risk for stroke (one non-sex-related CHA2DS2-VASc point) should be treated with an oral anticoagulant. METHODS AND RESULTS: We conducted a multi-country cohort study in Sweden, Denmark, Norway, and Scotland. In total, 59 076 patients diagnosed with AF at low stroke risk were included. We assessed the rates of stroke or major bleeding during treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), a vitamin K antagonist (VKA), or no treatment, using inverse probability of treatment weighted (IPTW) Cox regression. In untreated patients, the rate for ischaemic stroke was 0.70 per 100 person-years and the rate for a bleed was also 0.70 per 100 person-years. Comparing NOAC with no treatment, the stroke rate was lower [hazard ratio (HR) 0.72; 95% confidence interval (CI) 0.56-0.94], and the rate for intracranial haemorrhage (ICH) was not increased (HR 0.84; 95% CI 0.54-1.30). Comparing VKA with no treatment, the rate for stroke tended to be lower (HR 0.81; 95% CI 0.59-1.09), and the rate for ICH tended to be higher during VKA treatment (HR 1.37; 95% CI 0.88-2.14). Comparing NOAC with VKA treatment, the rate for stroke was similar (HR 0.92; 95% CI 0.70-1.22), but the rate for ICH was lower during NOAC treatment (HR 0.63; 95% CI 0.42-0.94). CONCLUSION: These observational data suggest that NOAC treatment may be associated with a positive net clinical benefit compared with no treatment or VKA treatment in patients at low stroke risk, a question that can be tested through a randomized controlled trial.
引用
- Komen, Pottegård, Mantel-Teeuwisse, et al. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. Eur Heart J. 2022. PMID: 35265981. doi:10.1093/eurheartj/ehac111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。